Amarin Corp Plcuk AMRN
NASDAQ AMRN
$14.09 +0.03 (+0.21%)
At close: Aug 21, 2026 · 4:00 PM EDT

Amarin Corp Plcuk (AMRN) Cash from Investing Activities (2010 - 2026)

Amarin Corp Plc\Uk (AMRN) posted quarterly Cash from Investing Activities of $6.1 million for Q2 2026, down 50.54% year-over-year from $12.4 million in Q2 2025, and up 173.97% quarter-over-quarter from -$8.3 million in Q1 2026.

Amarin Corp Plcuk (AMRN) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Amarin Corp Plc\Uk (AMRN) has reported Cash from Investing Activities for 16 consecutive years, with $6.1 million the latest figure, recorded in Q2 2026.

  • In Q2 2026, Cash from Investing Activities fell 50.54% year-over-year to $6.1 million; the TTM figure through Jun 2026 stood at -$17.8 million (up 67.58% YoY), while the FY2025 annual figure was $8.8 million, up 119.2% from the prior year.
  • Cash from Investing Activities grew to $6.1 million in Q2 2026 per AMRN's latest filing, from -$8.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $99.0 million in Q1 2022 and bottomed at -$71.0 million in Q4 2023.
  • Historically, Cash from Investing Activities has averaged $6.1 million across 5 years, with a median of $5.4 million in 2024.
  • On a YoY basis, Cash from Investing Activities climbed as much as 246.45% in 2024 and fell as far as 283.8% in 2024.
  • Amarin Corp Plc\Uk's Cash from Investing Activities stood at -$27.8 million in 2022, then plunged by 155.22% to -$71.0 million in 2023, then surged by 67.83% to -$22.8 million in 2024, then jumped by 84.61% to -$3.5 million in 2025, then jumped by 274.57% to $6.1 million in 2026.
  • Business Quant data shows AMRN's Cash from Investing Activities at $6.1 million in Q2 2026, -$8.3 million in Q1 2026, and -$3.5 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -1.11 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -1.20 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -5.60 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -3.11 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -2.91 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -569.00 Mn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -10.35 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 2.11 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 2.68 Bn
10 Amarin Corp Plcuk 5.86 Bn 5.54 Bn 14.99 Mn 6.14 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 6.14 Mn
Jun 30, 2026 6.14 Mn
Mar 31, 2026 -8.30 Mn
Mar 31, 2026 -8.30 Mn
Dec 31, 2025 -3.52 Mn
Dec 31, 2025 -3.52 Mn
Sep 30, 2025 -12.13 Mn
Sep 30, 2025 -12.13 Mn
Jun 30, 2025 12.41 Mn
Jun 30, 2025 12.41 Mn
Mar 31, 2025 12.06 Mn
Mar 31, 2025 12.06 Mn
Dec 31, 2024 -22.84 Mn
Dec 31, 2024 -22.84 Mn
Sep 30, 2024 -56.55 Mn
Sep 30, 2024 -56.55 Mn
Jun 30, 2024 4.70 Mn
Jun 30, 2024 4.70 Mn
Mar 31, 2024 28.72 Mn
Mar 31, 2024 28.72 Mn